Regis Healthcare shares down 2% as CEO resigns

Dr Mellors will step down as CEO after more than six years in the role.

| More on:
A man packs up a box of belongings at his desk as he prepares to leave the office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Regis Healthcare CEO has resigned and is pursuing an opportunity outside the aged care sector.
  • Despite being up 20% for the year, Regis shares have been on a wild ride, climbing 53% to $9.22 before a September funding update triggered a 35% sell-off.
  • With a CEO search underway and government funding reforms still bedding down, the market appears cautious, focused on execution, labour cost control, and delivery of FY26 earnings.

Shares in Regis Healthcare Ltd (ASX: REG) are down 2% after the aged care operator announced the resignation of Chief Executive Officer Dr Linda Mellors.

In an ASX release, Regis confirmed that Dr Mellors will step down after more than six years in the role, having decided to pursue an opportunity outside the aged care sector. She will remain in her position during a six-month notice period while the board conducts an executive search and manages a transition of responsibilities.

While leadership changes can prompt short-term uncertainty, today's share price reaction also needs to be viewed in the context of a volatile year for Regis investors.

A strong year with a sharp reversal

On the surface, Regis shares are still up about 20% year to date, having started the year around $6. However, that headline gain masks a much bumpier journey.

Earlier in 2025, optimism around Regis shares, powered by sector reform and operational improvements, drove the Regis share price up as much as 53%, peaking at $9.22. That rally came to an abrupt end on 22 September, when the company released a funding update outlining the impact of changes to government aged care funding models.

At the time, Regis revealed that increases under the Australian National Aged Care Classification (AN-ACC) framework would fall well short of expectations, largely due to reweighting across resident classifications. The announcement triggered a sharp reassessment by the market, with the share price falling around 35% back to $6, effectively wiping out the year's gains.

Why today's news matters

Against that backdrop, the resignation of the CEO introduces another layer of uncertainty. Dr Mellors led Regis through major industry upheavals, including the Royal Commission into Aged Care, the COVID-19 pandemic, and the rollout of the new Aged Care Act. The board acknowledged her role in stabilising and transforming the business, noting that Regis remains in a strong financial and operational position.

However, investors appear cautious about leadership change at a time when the company is still adjusting to funding pressures and wage cost increases across the sector.

What's next for Regis?

An executive search is now underway, and the company has emphasised continuity during the transition period. For shareholders, attention will likely return to how Regis navigates government funding reforms, manages labour costs, and delivers on its FY26 earnings outlook.

For now, the market reaction suggests investors are taking a "wait and see" approach, wary after September's funding shock, but still recognising the longer-term recovery story remains intact.

Motley Fool contributor Kevin Gandiya has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

woman testing substance in laboratory dish, csl share price
Share Market News

After a 73% surge this ASX healthcare share looks far from done

Brokers are upbeat, and some see possible gains of 90% in 2026.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which biotech's shares are surging higher on US patent news?

Investors like what they see from this drug company.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This biotech company's shares are on a tear – again – after another contract win

A new contract with a prestigious US institution spells good news for shareholders.

Read more »

Child with superhero mask and cape flies after jumping on sofa
AI Stocks

3 of the fastest-growing stocks on the planet in 2025

These stocks soared in 2025.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Could CSL shares outperform the ASX 200 in 2026?

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better.

Read more »

A man holds his head in his hands after seeing bad news on his laptop screen.
Healthcare Shares

Why did CSL shares crash 39% in 2025?

Should you be buying the dip? Let's find out.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Why 4DMedical shares are jumping 14% today

4DMedical shares climb on a new CFO appointment as investors focus on US expansion and rising use of its lung…

Read more »

A business woman flexes her muscles overlooking a city scape below.
Healthcare Shares

Why I plan to buy this incredible ASX 200 stock in 2026

A 33% pullback has put Pro Medicus back in focus. Here’s why I’m preparing to buy its shares in 2026.

Read more »